|
Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ operable breast cancer: 5-year outcomes of NSABP protocol B-41. |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Incyte |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Stemnion |
Research Funding - Incyte |
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; Genentech/Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Research Funding - Roche/Genentech (Inst) |
|
|
Honoraria - Genomic Health; RNA Dx |
Consulting or Advisory Role - Genomic Health; RNA Dx |
Research Funding - Genomic Health (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
|
|
Honoraria - Clinigen Group; Roche |
Consulting or Advisory Role - Clinigen Group; Genentech/Roche |
Research Funding - Genentech; Puma Biotechnology; Roche |
Travel, Accommodations, Expenses - Genentech/Roche |
|
|
Honoraria - Genentech/Roche; Genomic Health |
Consulting or Advisory Role - Celgene; Genomic Health; GlaxoSmithKline; Novartis; Pfizer; Ventana Medical Systems |
Speakers' Bureau - Genentech/Roche; Genomic Health |
Travel, Accommodations, Expenses - Celgene; Genentech/Roche; Genomic Health |
|
|
Research Funding - Bayer (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Abbvie; Genentech; GHI Pharma |